Trends in the proportion of patients who received NAT for different age groups are shown in Fig. 2A. The proportion of gastric cancer patients who received NAT decreased with age from < 65 years (802/945, 84.9%) to ≥ 85 years (3/131, 2.3%). Here, BRD2 is linked to gastric cancer.